These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 3166242

  • 1. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.
    Walenga JM, Bara L, Petitou M, Samama M, Fareed J, Choay J.
    Thromb Res; 1988 Jul 01; 51(1):23-33. PubMed ID: 3166242
    [Abstract] [Full Text] [Related]

  • 2. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP, Bernat A, Gaich C, Herbert M.
    Thromb Haemost; 2002 Feb 01; 87(2):238-44. PubMed ID: 11858483
    [Abstract] [Full Text] [Related]

  • 3. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
    Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J.
    Thromb Res; 1987 Apr 15; 46(2):187-98. PubMed ID: 3603420
    [Abstract] [Full Text] [Related]

  • 4. Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
    Herbert JM, Hérault JP, Bernat A, van Amsterdam RG, Vogel GM, Lormeau JC, Petitou M, Meuleman DG.
    Circ Res; 1996 Sep 15; 79(3):590-600. PubMed ID: 8781492
    [Abstract] [Full Text] [Related]

  • 5. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.
    Buchanan MR, Boneu B, Ofosu F, Hirsh J.
    Blood; 1985 Jan 15; 65(1):198-201. PubMed ID: 3965047
    [Abstract] [Full Text] [Related]

  • 6. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
    Herbert JM, Hérault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, van Boeckel C, Hoffmann P, Meuleman DG.
    Blood; 1998 Jun 01; 91(11):4197-205. PubMed ID: 9596667
    [Abstract] [Full Text] [Related]

  • 7. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U, Ku P, Malinowski J, Zhu BY, Scarborough RM, Marlowe CK, Wong PW, Lin PH, Hollenbach SJ.
    Eur J Pharmacol; 2000 Apr 21; 395(1):51-9. PubMed ID: 10781674
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
    Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J.
    Thromb Res; 1994 Sep 15; 75(6):609-16. PubMed ID: 7831680
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
    Carrie D, Caranobe C, Saivin S, Houin G, Petitou M, Lormeau JC, Van Boeckel C, Meuleman D, Boneu B.
    Blood; 1994 Oct 15; 84(8):2571-7. PubMed ID: 7919374
    [Abstract] [Full Text] [Related]

  • 10. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
    Meuleman DG, Hobbelen PM, Van Dinther TG, Vogel GM, Van Boeckel CA, Moelker HC.
    Semin Thromb Hemost; 1991 Oct 15; 17 Suppl 1():112-7. PubMed ID: 2068564
    [Abstract] [Full Text] [Related]

  • 11. Antithrombotic activity and its relationship to in vitro anticoagulant effects.
    Gray E, Padilla A, Barrowcliffe TW.
    Haemostasis; 1993 Mar 15; 23 Suppl 1():99-102. PubMed ID: 8388358
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity.
    Vogel GM, Meuleman DG, Van Dinther TG, Buijsman R, Princen AW, Smit MJ.
    J Thromb Haemost; 2003 Sep 15; 1(9):1945-54. PubMed ID: 12941035
    [Abstract] [Full Text] [Related]

  • 14. Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity.
    Walenga JM, Petitou M, Samama M, Fareed J, Choay J.
    Thromb Res; 1988 Dec 15; 52(6):553-63. PubMed ID: 3232125
    [Abstract] [Full Text] [Related]

  • 15. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa.
    Lormeau JC, Herault JP.
    Thromb Haemost; 1995 Dec 15; 74(6):1474-7. PubMed ID: 8772223
    [Abstract] [Full Text] [Related]

  • 16. Anticoagulant and antithrombotic actions of a semisynthetic beta-1,3-glucan sulfate.
    Alban S, Jeske W, Welzel D, Franz G, Fareed J.
    Thromb Res; 1995 May 01; 78(3):201-10. PubMed ID: 7631300
    [Abstract] [Full Text] [Related]

  • 17. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222.
    Tew CJ, Lane DA, Thompson E, Ireland H, Curtis JR.
    Br J Haematol; 1988 Nov 01; 70(3):335-40. PubMed ID: 2849981
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
    Hollenbach S, Sinha U, Lin PH, Needham K, Frey L, Hancock T, Wong A, Wolf D.
    Thromb Haemost; 1994 Mar 01; 71(3):357-62. PubMed ID: 8029801
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.